NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球醫藥品原料藥 (API)市場(2021年-2025年)

Global Active Pharmaceutical Ingredients Market 2021-2025

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 986234
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
全球醫藥品原料藥 (API)市場(2021年-2025年) Global Active Pharmaceutical Ingredients Market 2021-2025
出版日期: 2021年01月28日內容資訊: 英文 120 Pages
簡介

全球醫藥品原料藥 (API的)市場規模在2021年∼2025年間,預測將成長到645億3000萬美元,在預測期間內預計將以6%的年複合成長率推移。市場成長的主要因素有發展中國家不斷發展的API製造,提升核心競爭力為焦點的需求。

本報告提供醫藥品原料藥 (API)市場調查,提供市場概要,市場成長要素及阻礙因素分析,各類型·各地區的市場規模的變化與預測,供應商分析,市場機會等全面性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模2020
  • 市場預測:從2020年∼2025年的預測

波特的五力分析

各製造類型的市場區隔

  • 市場·市場區隔
  • 各製造類型比較
  • 專屬式API-市場規模與預測(2020年∼2025年)
  • 契約API-市場規模與預測(2020年∼2025年)
  • 各製造類型的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 亞太地區-市場規模與預測(2020年∼2025年)
  • 北美-市場規模與預測(2020年∼2025年)
  • 歐洲-市場規模與預測(2020年∼2025年)
  • 其他地區-市場規模與預測(2020年∼2025年)
  • 主要的主要國家
  • 地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

競爭模式

業者情勢

創造性破壞狀況

供應商分析

成為對象的供應商

供應商的市場定位

Amneal Pharmaceuticals Inc.

kadiraherusukea股票企業

Dr. Reddy's Laboratories Ltd.

GlaxoSmithKline PlcPlc

  • Koninklijke DSM NV
  • 我的欄NV
  • 諾華AG
  • 輝瑞股票企業
  • Sun製藥股票企業
  • tebafamashutikaruindasutorizurimiteddo。

附錄

目錄
Product Code: IRTNTR40608

Technavio has been monitoring the active pharmaceutical ingredients market and it is poised to grow by $ 64.53 bn during 2021-2025, progressing at a CAGR of 6% during the forecast period. Our report on the active pharmaceutical ingredients market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the evolving API manufacturing scenario in developing countries and the growing need to focus on core competencies. In addition, evolving API manufacturing scenario in developing countries is anticipated to boost the growth of the market as well.

The active pharmaceutical ingredients market analysis includes type segment and geographical landscapes.

Technavio's active pharmaceutical ingredients market is segmented as below:

By Type

Captive APIs

Contract APIs

By Geography

APAC

North America

Europe

ROW

This study identifies the Increasing number of type II DMFs as one of the prime reasons driving the active pharmaceutical ingredients market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the active pharmaceutical ingredients market covers the following areas:

Active pharmaceutical ingredients market sizing

Active pharmaceutical ingredients market forecast

Active pharmaceutical ingredients market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredients market vendors that include Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., GlaxoSmithKline Plc, Koninklijke DSM NV, Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. Also, the active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Manufacturing Type

  • Market segments
  • Comparison by manufacturing type
  • Captive APIs - Market size and forecast 2020-2025
  • Contract APIs - Market size and forecast 2020-2025
  • Market opportunity by manufacturing type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • APAC - Market size and forecast 2020-2025
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

Competitive scenario

Vendor landscape

Landscape disruption

Vendor Analysis

Vendors covered

Market positioning of vendors

Amneal Pharmaceuticals Inc.

Cadila Healthcare Ltd.

Dr. Reddy's Laboratories Ltd.

GlaxoSmithKline Plc

  • Koninklijke DSM NV
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ billion)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Other1 - Market share 2020-2025 (%)
  • 22: Comparison by Other1
  • 23: Captive APIs - Market size and forecast 2020-2025 ($ billion)
  • 24: Captive APIs - Year-over-year growth 2020-2025 (%)
  • 25: Contract APIs - Market size and forecast 2020-2025 ($ billion)
  • 26: Contract APIs - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Other1
  • 28: Customer landscape
  • 29: Market share by geography 2020-2025 (%)
  • 30: Geographic comparison
  • 31: APAC - Market size and forecast 2020-2025 ($ billion)
  • 32: APAC - Year-over-year growth 2020-2025 (%)
  • 33: North America - Market size and forecast 2020-2025 ($ billion)
  • 34: North America - Year-over-year growth 2020-2025 (%)
  • 35: Europe - Market size and forecast 2020-2025 ($ billion)
  • 36: Europe - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ billion)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ billion)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Amneal Pharmaceuticals Inc. - Overview
  • 48: Amneal Pharmaceuticals Inc. - Business segments
  • 49: Amneal Pharmaceuticals Inc. - Key offerings
  • 50: Amneal Pharmaceuticals Inc. - Key customers
  • 51: Amneal Pharmaceuticals Inc. - Segment focus
  • 52: Cadila Healthcare Ltd. - Overview
  • 53: Cadila Healthcare Ltd. - Business segments
  • 54: Cadila Healthcare Ltd. - Key offerings
  • 55: Cadila Healthcare Ltd. - Key customers
  • 56: Cadila Healthcare Ltd. - Segment focus
  • 57: GlaxoSmithKline Plc - Overview
  • 58: GlaxoSmithKline Plc - Business segments
  • 59: GlaxoSmithKline Plc - Key offerings
  • 60: GlaxoSmithKline Plc - Key customers
  • 61: GlaxoSmithKline Plc - Segment focus
  • 62: Koninklijke DSM NV - Overview
  • 63: Koninklijke DSM NV - Business segments
  • 64: Koninklijke DSM NV - Key offerings
  • 65: Koninklijke DSM NV - Key customers
  • 66: Koninklijke DSM NV - Segment focus
  • 67: Mylan NV - Overview
  • 68: Mylan NV - Business segments
  • 69: Mylan NV - Key offerings
  • 70: Mylan NV - Key customers
  • 71: Mylan NV - Segment focus
  • 72: Novartis AG - Overview
  • 73: Novartis AG - Business segments
  • 74: Novartis AG - Key offerings
  • 75: Novartis AG - Key customers
  • 76: Novartis AG - Segment focus
  • 77: Pfizer Inc. - Overview
  • 78: Pfizer Inc. - Business segments
  • 79: Pfizer Inc. - Key offerings
  • 80: Pfizer Inc. - Key customers
  • 81: Pfizer Inc. - Segment focus
  • 82: Sun Pharmaceutical Industries Ltd. - Overview
  • 83: Sun Pharmaceutical Industries Ltd. - Business segments
  • 84: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 85: Sun Pharmaceutical Industries Ltd. - Key customers
  • 86: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 87: Teva Pharmaceutical Industries Ltd. - Overview
  • 88: Teva Pharmaceutical Industries Ltd. - Business segments
  • 89: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 90: Teva Pharmaceutical Industries Ltd. - Key customers
  • 91: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 92: Currency conversion rates for US$
  • 93: Research Methodology
  • 94: Validation techniques employed for market sizing
  • 95: Information sources
  • 96: List of abbreviations